latest news releases from the newsroom
StockPickReport: $100 Oil?
SHREVEPORT, La., Oct. 26, 2004 (PRIMEZONE) -- Stock-Letter-Daily.Com (http://www.stock-letter-daily.com - an affiliate site of StockPickReport, the web's only non-mainstream stock rating service), rates Microsoft, General Electric, Nokia Corporation, Micron Technology Inc
StockPickReport: Time to Buy Semiconductor Stocks
SHREVEPORT, La., Oct. 26, 2004 (PRIMEZONE) -- Stock-Letter-Daily.Com (http://www.stock-letter-daily.com -- an affiliate site of StockPickReport, the web's only non-mainstream stock rating service), rates Merrill Lynch Semiconductor HOLDRS, Apple Computer Inc, Hewlett-Packard Co, International Business Machines Corporation
StockPickReport: Motorola is a Short-Term Sell
SHREVEPORT, La., Oct. 26, 2004 (PRIMEZONE) -- Stock-Letter-Daily.Com (http://www.stock-letter-daily.com -- an affiliate site of StockPickReport, the web's only non-mainstream stock rating service), rates Motorola Inc, Research In Motion Ltd, Nextel Communications Inc, Check Point Software Technologies Ltd.
StockPickReport: `Cisco Sell Rating'
SHREVEPORT, La., Oct. 26, 2004 (PRIMEZONE) -- Stock-Letter-Daily.Com (http://www.stock-letter-daily.com -- an affiliate site of StockPickReport, the web's only non-mainstream stock rating service), rates Cisco Systems, Nortel, Time Warner Inc, Sprint FON Group.
Market Pulse Announces its Stocks to Watch List for Tuesday, October 26, 2004: GDNO, AMTX, YHOO, LBTS!
ATLANTA, Oct. 26, 2004 (PRIMEZONE) -- Market Pulse is pleased to introduce our featured stock, Golden Opportunity Resources, Inc.(Pink Sheets:GDNO), to the investment community! Golden Opportunity Resources is new to Market Pulse and is a junior oil and gas exploration company focused on finding and developing undervalued oil and gas assets worldwide. GDNO just had drill update news out after yesterday's bell! Investors need to be watching this one closely! Other notable stocks that look great lately from a fundamental and technical perspective include:
Optio Software, Inc.
QAD Inc. and Optio Software Expand Worldwide Alliance
ALPHARETTA, Ga., Oct. 26, 2004 (PRIMEZONE) -- Optio(r) Software (OTCBB:OPTO), a leading provider of document output management and forms automation solutions, today announces that QAD(tm) Inc., (Nasdaq:QADI) has added Optio e.ComIntegrate(tm) and DesignStudio(tm) to its worldwide Solution Center, an information portal used by the global QAD sales force. QAD sales consultants will use these Optio products to demonstrate how customers and prospects can add value to MFG/PRO(r) eB2 enterprise software.
Talking Stocks Issues Favorable Report on FinancialContent, Inc.
DALLAS, Oct. 26, 2004 (PRIMEZONE) -- Jeff Bishop, Senior Investment Analyst for TalkingStocks.com, a leading online destination for small-cap investors, has issued a favorable report on FinancialContent, Inc. (OTCBB:FCON). In the report, Mr. Bishop offers the rating of 'Long Term Attractive.' From today's report, Mr. Bishop summarizes some of the rationale: "We feel that FinancialContent represents a solid investment at current levels. Though the headline number of 130% revenue increase got the attention of many investors, it was quickly discounted due to the fact that a bulk of this gain was attributable to a one-time client acquisition. Investors who chose to dig a little deeper into the financial statements will realize that company's growth apart from the one-time gain was still quite remarkable -- over 40% internal growth."
Biovitrum AB and Pharmacopeia Form Strategic Research Alliance
STOCKHOLM, Sweden and PRINCETON, N.J., Oct. 26, 2004 (PRIMEZONE) -- Biovitrum AB and Pharmacopeia Drug Discovery, Inc. (Nasdaq:PCOP) today announced that they have entered into a multi-year drug discovery and development alliance. Biovitrum and Pharmacopeia will work together to identify and optimise small molecule lead compounds suitable for advancing into pre-clinical development for multiple targets within the metabolic disease area. Under the terms of this agreement, Biovitrum will access Pharmacopeia's unique drug discovery assets, including its multi-million compound collection of proprietary drug-like small molecules and its drug discovery expertise to identify and optimise leads. The alliance is structured to leverage Biovitrum's biology expertise and considerable domain experience in metabolic diseases. In the true spirit of a strategic alliance, Pharmacopeia will receive some initial funding to offset its research investment but will secure greater part of the return on its investment upon the successful achievement of pre-clinical and clinical milestones. Pharmacopeia will also receive royalties upon the commercialisation of any drugs resulting from the collaboration. Biovitrum will be responsible for development and will retain all marketing rights to collaboration products.